(ii) a polypeptide encoded by nucleic acid which hybridizes under stringent conditions to the complement of nucleic acid residues 682 to 1926 of SEQ ID NO: 2, said stringent conditions comprising hybridization in a solution containing 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6-8), 0.1% sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% sodium dodecyl sulfate (SDS) and 10% dextran sulfate at 42°C followed by wash at 42°C in 0.2 x SSC and 0.1% SDS, and which has both the ability to stimulate actin polymerization and the ability to bind to a protein tyrosine phosphatase which (a) possesses a non-catalytic domain comprising a region rich in proline, serine and threonine residues and a C-terminal 20 amino acid segment which is rich in proline residues, and (b) defines at least one SH3 binding domain.

REMARKS

The foregoing amendment is fully supported by the specification as originally filed and does not add new matter. Support can be found, for example, at page 3, lines 3-5, and throughout the specification.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Applicants are pleased to note the Examiner's indication in the Advisory Action that most of the issues underlying the §112, §102 and §103 rejections may be resolved by entry of the amendments in the Amendment After Final.

However, in the Advisory Action, the Examiner expressed concern that several phrases in claim 23 were not supported by the specification. Support for the phrases "to stimulate or inhibit the polymerization of actin monomers induced by over-expression of the PSTPIP polypeptide within a cell" and "identifying an agonist antibody if there is an increase in the level of actin polymerization and an antagonist antibody if there is a decrease in the level of actin polymerization" can be found, for example, at page 8, lines 29-38, in the definitions of "agonist" and "antagonist" and throughout the specification.